Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Kazia Therapeutics Product Paxalisib Beats Temozolomide in Overall Survival in Mid-Phase Trial

August 25, 2020 0

The US FDA Awards Fast Track Designation to Paxalisib for Glioblastoma Kazia Therapeutics Ltd (KZIA) – an …

What’s Going on with Gene Therapy?

August 25, 2020 0

Recent Gene Therapy News On August 20, 2020 Audentes Therapeutics, which was taken over by Astellas …

The FDA’s Complete Response Letters, Creating Investment Opportunities?

August 20, 2020 0

Yesterday, under Today’s Highlights, we posted that the U.S. FDA issued a Complete Response Letter (CRL) …

Gilead Sciences: An FDA Complete Response Letter Will Not Stop This Firm from Rallying

August 19, 2020 0

Gilead Sciences Was Issued a CLR from the FDA for Filgotinib Gilead Sciences (GILD) is in …

A Royal Reception by Investors for CureVac. See Also: Good Oncology News for Bristol-Myers Squibb

August 17, 2020 0

CureVac is Publicy Trading on the NASDAQ CureVac is now publicly trading on the NASDAQ stock …

An Important Announcement from Sorrento Therapeutics

August 13, 2020 0

Sorrento Therapeutics Announcement Sorrento Therapeutics (SRNE) announced that it believes it has uncovered fraudulent attempts to …

Monopar Therapeutics: A Plan for a Test that Predicts COVID-19 Patients Who Might Likely Develop Severe Respiratory Failure

August 13, 2020 0

A Predictive COVID-19 Test? COVID-19 infected people are not all affected to the same degree with …

Intellia Therapeutics: Realizing the Dream of Curing Devastating Diseases

August 11, 2020 0

Intellia Therapeutics Reporting operational highlights and financial results for the second quarter ended June 30, 2020, Intellia …

Seres Therapeutics Oral Microbiome Product SER-109 Meets Trial Endpoint

August 10, 2020 0

Seres Therapeutics Oral Microbiome Product SER-109 for Recurrent C. Difficile Infection Meets Trial Endpoint SER-109 demonstrated …

Alterity Therapeutics: Treating Neurodegenerative Diseases?

August 5, 2020 0

When a small firm’s stock price soars, and more than doubles, curiosity pushes us to investigate. …

Regenxbio: Positive One-Year Data from the Firm’s Gene Therapy RGX-314 for Wet AMD

August 4, 2020 0

Regenxbio Positive Data for RGX-314 Regenxbio (RGNX) reported positive one-year data from patients in Cohorts 4 …

Compugen: A Stock To Keep

August 3, 2020 0

Compugen Compugen (CGEN) cancer immunotherapy’s predictive target computational discovery platforms enabled it to identify two checkpoint …

Inovio: Good News About the Firm’s COVID-19 Vaccine’s Capability and Durability

July 30, 2020 0

Inovio Inovio’s COVID-19 Vaccine INO-4800 Accomplished the Following: Durable antibody and T cell responses in rhesus …

Edesa Biotech Stock Price Soared. Will It Continue to Rise?

July 30, 2020 0

Edesa Biotech Filed an IND for EB05 Edesa Biotech (EDSA), a clinical-stage biopharmaceutical company, has filed …

Moderna News. See Also: Regeneron Antibody Cocktail Could Reach the Market in October

July 29, 2020 0

SARS-CoV-2 Virus Vaccines Moderna On Monday Moderna (MRNA) started its Phase 3 clinical trial on 30,000 …

The FDA Approved Gilead Sciences CAR T Cell Product Tecartus for Adults with Relapsed or Refractory Mantle Cell Lymphoma

July 27, 2020 0

Gilead Sciences CAR T Cell Product Tecartus Gets FDA Approval The U.S. FDA approved Kite - …

TCR2 Therapeutics Encouraging Oncology Results

July 27, 2020 0

TCR2 Therapeutics Announcement TCR2 Therapeutics (TCRR) – a clinical-stage immunotherapy company with a pipeline of novel T cell therapies …

Could Arbutus Biopharma’s Patent Harm Moderna?

July 24, 2020 0

Arbutus Biopharma and Moderna's Patent Challenge Arbutus Biopharma (ABUS) is a publicly-traded biopharmaceutical company dedicated to …

Jazz Pharmaceuticals: A New FDA Approval

July 22, 2020 0

People living with narcolepsy who develop cataplexy and excessive daytime sleepiness have a new treatment called Xywav, …

The Small Firm Whose Stock Soared in Yesterday’s Market

July 21, 2020 0

Firms' with COVID-19 Vaccines Stock Performance A look at the stock performance of the COVID-19 vaccine …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Kazia Therapeutics Product Paxalisib Beats Temozolomide in Overall Survival in Mid-Phase Trial

What’s Going on with Gene Therapy?

The FDA’s Complete Response Letters, Creating Investment Opportunities?

Gilead Sciences: An FDA Complete Response Letter Will Not Stop This Firm from Rallying

A Royal Reception by Investors for CureVac. See Also: Good Oncology News for Bristol-Myers Squibb

An Important Announcement from Sorrento Therapeutics

Monopar Therapeutics: A Plan for a Test that Predicts COVID-19 Patients Who Might Likely Develop Severe Respiratory Failure

Intellia Therapeutics: Realizing the Dream of Curing Devastating Diseases

Seres Therapeutics Oral Microbiome Product SER-109 Meets Trial Endpoint

Alterity Therapeutics: Treating Neurodegenerative Diseases?

Regenxbio: Positive One-Year Data from the Firm’s Gene Therapy RGX-314 for Wet AMD

Compugen: A Stock To Keep

Inovio: Good News About the Firm’s COVID-19 Vaccine’s Capability and Durability

Edesa Biotech Stock Price Soared. Will It Continue to Rise?

Moderna News. See Also: Regeneron Antibody Cocktail Could Reach the Market in October

The FDA Approved Gilead Sciences CAR T Cell Product Tecartus for Adults with Relapsed or Refractory Mantle Cell Lymphoma

TCR2 Therapeutics Encouraging Oncology Results

Could Arbutus Biopharma’s Patent Harm Moderna?

Jazz Pharmaceuticals: A New FDA Approval

The Small Firm Whose Stock Soared in Yesterday’s Market